Multivariable Cox regression clinical stage III and IV NSCLC; (aHR (95% CI)) for mortality associated with time-to-treatment
| Time-to-treatment quartiles (days) | Stage III chemoradiotherapy (N=2772) | Stage III radiotherapy (N=1359) | Stage III systemic therapy (N=907) | Stage IV systemic therapy (N=5268) | ||||
| aHR* (95% CI) | P value | aHR† (95% CI) | P value | aHR‡ (95% CI) | P value | aHR§ (95% CI) | P value | |
| 1 (0–21 days) | Ref | - | Ref | - | Ref | - | Ref | - |
| 2 (22–35 days) | 1.06 (0.92 to 1.23) | 0.4072 | 0.65 (0.51 to 0.82) | 0.0002 | 0.92 (0.73 to 1.15) | 0.4495 | 0.89 (0.82 to 0.98) | 0.0169 |
| 3 (36–49 days) | 1.09 (0.93 to 1.28) | 0.2833 | 0.55 (0.44 to 0.69) | <0.0001 | 0.84 (0.66 to 1.07) | 0.l540 | 0.84 (0.77 to 0.93) | 0.0005 |
| 4 (>49 days) | 1.12 (0.95 to 1.32) | 0.1612 | 0.59 (0.47 to 0.73) | <0.0001 | 0.72 (0.56 to 0.91) | 0.0062 | 0.77 (0.70 to 0.85) | <0.0001 |
*Time-to-treatment adjusted for gender, age, socioeconomic status, performance status, histology.
†Time-to-treatment adjusted for age, socioeconomic status, year of diagnosis, performance status, histology.
‡Time-to-treatment adjusted for age, performance status, histology.
§Time-to-treatment adjusted for gender, age, performance status, histology, distant metastasis (cM1a vs cM1b/cM1c), type of systemic therapy (targeted vs chemo/immunotherapy).
aHR, adjusted HR; NSCLC, non-small cell lung cancer.